ArticleVirchows Archiv : an international journal of pathology2026
JAK2 and NOTCH2 in gastric cancer - NOTCH2 is an independent prognosticator of poor patient outcome.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric carcinomas occasionally harbor genetic alterations of JAK2 and NOTCH2. In this study we investigated the tumor biological significance of JAK2 and NOTCH2 in gastric carcinoma. The expression of JAK2 and NOTCH2 was studied by immunohistochemistry using whole mount tissue sections obtained from 447 resection specimens of gastric adenocarcinomas. A Histoscore was generated and expression data were correlated with patient survival and clinicopathological patient characteristics. Both JAK2 and NOTCH2 were heterogeneously expressed intratumorally in gastric cancer. The number of cases showing high expression of JAK2 (5.4%) and NOTCH2 (3.4%) was low matching with genetic data retrieved from cBioPortal. NOTCH2 was an independent prognosticator of poor outcome (tumor-specific survival: 16.7 ± 1.5 months in the NOTCH2 "low" vs. 7.2 ± 0.7 months in the NOTCH2 "high" cohort; p = < 0.001). To the contrary, patients with little or no expression of JAK2 showed a worse tumor-specific survival (15.4 ± 1.3 months in the JAK2 "low" group vs. 19.5 ± 13.1 months in the JAK2 "high" group; p = 0.041). No correlation was found between expression of JAK2 and NOTCH2. JAK2 and NOTCH2 are differently expressed in gastric adenocarcinoms and of putative tumor biological significance. Particularly NOTCH2 turned out to be an independent prognosticator of poor patient outcome.
Indexed as
Identifiers
41986522What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.